The Platelecrit: The Role in Differential Diagnosis of Small Renal Masses

Reha Girgin 1 * , Önder Cinar 1, Ersan Bulut 1, Bulent Akduman 1, Gökhan Ceker 1
More Detail
1 Department of Urology, Medical Faculty, Bulent Ecevit University, Zonguldak, Turkey
* Corresponding Author
J CLIN MED KAZ, Volume 2, Issue 56, pp. 6-10. https://doi.org/10.23950/1812-2892-JCMK-00752
OPEN ACCESS 2160 Views 1343 Downloads
Download Full Text (PDF)

ABSTRACT

Objective: To evaluate the importance of preoperative plateletcrit value predicting malignancy in patients who undergo open surgery due to small renal masses.
Material and methods: Sixty-eight patients who underwent open partial or radical nephrectomy for renal masses were included in this retrospective study. In preoperative routine blood tests, renal ultrasonography and contrast-enhanced computed tomography were performed for all patients. Preoperative plateletcrit values were compared in patients with clear cell renal cell carcinoma (Group 1, 57 patients) and benign lesions (Group 2, 11 patients). The predictive ability of plateletcrit was analyzed by ROC-curves and Youden Index method was used to identify the cut-off value for plateletcrit.
Results: The mean age of patients was 57.33±8.65 years in Group 1 and 59.32±10.59 years in Group 2 (p=0.546). The mean tumor size was 31.1 ± 5.84 mm in Group 1 and 28.07 ±6.25 mm in Group 2 (p=0.132). The median plateletcrit value was 1858,21 ±268,49 in Group 1 and 2258,01±524,35 in Group 2 (p:0.017). The area under a ROC-curve was 0.756 (p<0.05) .
Conclusion: Preoperative plateletcrit values may predict renal masses that can not be distinguished radiologically. Our results must be confirmed by large and properly designed prospective, randomized trials.
Keywords: renal cell carcinoma, plateletcrit, platelets, inflammation

CITATION

Girgin R, Cinar Ö, Bulut E, Akduman B, Ceker G. The Platelecrit: The Role in Differential Diagnosis of Small Renal Masses. Journal of Clinical Medicine of Kazakhstan. 2020;2(56):6-10. https://doi.org/10.23950/1812-2892-JCMK-00752

REFERENCES

  • Ferlay J, Bray F, Pisani P, Parkin D. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base. IARC Press. 2004; 5.
  • Patard JJ, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Prognostic significance of the mode of detection in renal tumours. BJU Int. 2002; 90(4):358-363. https://doi.org/10.1046/j.1464-410X.2002.02910.x
  • McNichols DW, Segura JW, DeWeerd JH. Renal cell carcinoma: long-term survival and late recurrence. J. Urol. 1981; 126(1):17-23. https://doi.org/10.1016/S0022-5347(17)54359-1
  • Caoili EM, Davenport MS. Role of percutaneous needle biopsy for renal masses. Semin Intervent Radiol. 2014; 31:20-26. https://doi.org/10.1055/s-0033-1363839
  • Jeldres C, Sun M, Liberman D, Lughezzani G, de la Taille A, Tostain J, et al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J Urol. 2009; 182(6):2585-2589. https://doi.org/10.1016/j.juro.2009.08.053
  • Lane BR, Babineau D, Kattan MW, Novick AC, Gill IS, Zhou M, Weight CJ, Campbell SC. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007; 178(2):429-434. https://doi.org/10.1016/j.juro.2007.03.106
  • Johnson DC, Vukina J, Smith AB, Meyer AM, Wheeler SB, Kuo TM, et al. Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population-level burden estimate. J Urol. 2014. https://doi.org/10.1016/j.juro.2014.07.102
  • Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454:436-44. https://doi.org/10.1038/nature07205
  • Poole EM, Lee IM, Ridker PM, Buring JE, Hankinson SE, Tworoger SS. A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer. Am J Epidemiol. 2013; 178:1256-64. https://doi.org/10.1093/aje/kwt098
  • Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015; 114:449-58. https://doi.org/10.1160/TH14-12-1067
  • Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelets effects on tumor growth. Seminars in oncology. 2014; 41:359-69. https://doi.org/10.1053/j.seminoncol.2014.04.006
  • Goubran H, Sabry W, Kotb R, Seghatchian J, Burnouf T. Platelet microparticles and cancer: An intimate cross-talk. Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis. 2015; 53:168-72. https://doi.org/10.1016/j.transci.2015.10.014
  • Akpinar I, Sayin MR, Gursoy YC, Karabag T, Kucuk E, Buyukuysal MC, et al. Plateletcrit. A platelet marker associated with saphenous vein graft disease. Herz. 2014; 39(1):142-8. https://doi.org/10.1007/s00059-013-3798-y
  • Ficarra V, Brunelli M, Cheng L, Kirkali Z, Lopez-Beltran A, Martignoni G, et al. Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol. 2010; 58:655-68. https://doi.org/10.1016/j.eururo.2010.08.001
  • Hutterer GC, Stoeckigt C, Stojakovic T, Jesche J, Eberhard K, Pummer K, et al. Low preoperative lymphocytemonocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma. Urol Oncol. 2014; 32:1041-8. https://doi.org/10.1016/j.urolonc.2014.04.001
  • Pichler M, Hutterer GC, Stojakovic T, Mannweiler S, Pummer K, Zigeuner R. High plasma fibrinogen level represents an independent negative prognostic fator regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of nonmetastatic renal cell carcinoma patients. Br J Cancer. 2013; 109:1123-9. https://doi.org/10.1038/bjc.2013.443
  • Semple JW, Italiano JE, Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011; 11(4):264-274. https://doi.org/10.1038/nri2956
  • Huang HS, Chang HH. Platelets in inflammation and immune modulations: functions beyond hemostasis. Arch Immunol Ther Exp (Warsz). 2012; 60(6):443-451. https://doi.org/10.1007/s00005-012-0193-y
  • Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol. 2013; 35(3):254-261. https://doi.org/10.1111/ijlh.12084 
  • Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015; 126(5):582-8. https://doi.org/10.1182/blood-2014-08-531582
  • Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J. 2001; 22:1561-71. https://doi.org/10.1053/euhj.2000.2515
  • Jae Woo Park, Chul-Hwan Kim, Yong Chan Ha, Moon Young Kim, Sung Min Park. Count of platelet and mean platelet volume score: serologic prognostic factor in patients with oral squamous cell carcinoma. J Korean Assoc Oral Maxillofac Surg. 2017; 43:305-311 https://doi.org/10.5125/jkaoms.2017.43.5.305
  • Osada J, Rusak M, Kamocki Z, Dabrowska MI, Kedra B. Platelet activation in patients with advanced gastric cancer. Neoplasma. 2010; 57:145-50. https://doi.org/10.4149/neo_2010_02_145
  • Mutlu H, Artis TA, Erden A, Akca Z. Alteration in mean platelet volume and platicrit values in patients with cancer that developed thrombosis. Clin Appl Thromb Hemost. 2013; 19:331-3. https://doi.org/10.1177/1076029611433644
  • Yun-Sok Ha, Jae-Wook Chung, So Young Chun, Seock Hwan Choi, Jun Nyung Lee, Bum Soo Kim, et al. Impact of preoperative thrombocytosis on prognosis after surgical treatment in pathological T1 and T2 renal cell carcinoma: results of a multi-institutional comprehensive study. Oncotarget. 2017; 8(38):64449-64458. https://doi.org/10.18632/oncotarget.16136
  • Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999; 59:1295-300.
  • Cerit L, Cerit Z. Relationship between coronary tortuosity and plateletcrit coronary tortuosity and plateletcrit. Cardiovasc J Afr. 2017; 23;28(6):385-388. https://doi.org/10.5830/CVJA-2017-023
  • Sacit Nuri Gorgel , Kutan Ozer , Osman Kose , Ahmet Selçuk Dindar. Can preoperative neutrophil lymphocyte ratio predict malignancy in patients undergoing partial nephrectomy because of renal mass? Int Braz J Urol. 2017; 43:XX-XX
  • Wang J, Liu Y, Zhang N, Li X, Xin P, Bi J, Kong C. Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer. Oncotarget. 2017; 10;8(41):70874-70882 https://doi.org/10.18632/oncotarget.20147
  • A.K. Olsson, J. Cedervall .The pro-inflammatory role of platelets in cancer. Platelets. 2018; 27:1-5. https://doi.org/10.1080/09537104.2018.1453059